海翔药业
(002099)
| 流通市值：89.02亿 | | | 总市值：89.19亿 |
| 流通股本：16.16亿 | | | 总股本：16.19亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 486,432,558.84 | 1,938,465,657.86 | 1,444,477,964.62 | 1,038,840,461.32 |
| 营业收入 | 486,432,558.84 | 1,938,465,657.86 | 1,444,477,964.62 | 1,038,840,461.32 |
| 二、营业总成本 | 466,678,445.96 | 1,859,241,448.52 | 1,375,713,221.67 | 962,350,478.7 |
| 营业成本 | 364,118,695.46 | 1,420,156,018.71 | 1,049,648,513.54 | 746,611,835.76 |
| 税金及附加 | 8,884,372.07 | 28,993,591.14 | 19,640,680.13 | 12,759,964.03 |
| 销售费用 | 2,712,154.25 | 33,253,110.97 | 22,610,881.65 | 14,065,328.86 |
| 管理费用 | 69,258,774.44 | 307,458,090.96 | 211,600,191.98 | 144,131,334.62 |
| 研发费用 | 30,648,501.47 | 129,445,758.14 | 97,696,518.45 | 64,219,777.28 |
| 财务费用 | -8,944,051.73 | -60,065,121.4 | -25,483,564.08 | -19,437,761.85 |
| 其中:利息费用 | 8,043,340.68 | 28,797,382.55 | 22,976,121.9 | 18,709,621.08 |
| 其中:利息收入 | 12,026,051.7 | 55,849,902.64 | 44,523,751.07 | 25,549,658.79 |
| 加:公允价值变动收益 | 3,050,776.04 | -16,490,493.01 | 336,069.83 | 6,759,442.01 |
| 加:投资收益 | 1,846,487.16 | 8,783,002.76 | 6,755,798.04 | -7,058,395.92 |
| 资产处置收益 | -98,061.31 | 1,037,057.82 | 547,933.61 | 365,093.08 |
| 资产减值损失(新) | -11,568,766.81 | -425,167,031.6 | -93,574,540.94 | -49,769,975.99 |
| 信用减值损失(新) | -2,502,471.14 | -4,543,717.64 | 3,214,636.33 | -2,574,979.14 |
| 其他收益 | 5,516,173.25 | 21,013,646.41 | 15,670,918.24 | 10,994,398.47 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 15,998,250.07 | -336,143,325.92 | 1,715,558.06 | 35,205,565.13 |
| 加:营业外收入 | 704,108.51 | 2,751,267.6 | 2,047,127.06 | 1,581,460.32 |
| 减:营业外支出 | 4,103,343.9 | 3,489,171.95 | 675,883.68 | 287,253.65 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 12,599,014.68 | -336,881,230.27 | 3,086,801.44 | 36,499,771.8 |
| 减:所得税费用 | 4,285,579.56 | -2,993,768.36 | -7,147,511.18 | -218,947.08 |
| 六、净利润 | 8,313,435.12 | -333,887,461.91 | 10,234,312.62 | 36,718,718.88 |
| 持续经营净利润 | 8,313,435.12 | -333,887,461.91 | 10,234,312.62 | 36,718,718.88 |
| 归属于母公司股东的净利润 | 9,229,942.41 | -330,267,195.37 | 11,979,756.66 | 38,102,495.42 |
| 少数股东损益 | -916,507.29 | -3,620,266.54 | -1,745,444.04 | -1,383,776.54 |
| (一)基本每股收益 | 0.01 | -0.21 | 0.01 | 0.02 |
| (二)稀释每股收益 | 0.01 | -0.21 | 0.01 | 0.02 |
| 八、其他综合收益 | - | 3,828,942.94 | - | - |
| 归属于母公司股东的其他综合收益 | - | 3,828,942.94 | - | - |
| 九、综合收益总额 | 8,313,435.12 | -330,058,518.97 | 10,234,312.62 | 36,718,718.88 |
| 归属于母公司股东的综合收益总额 | 9,229,942.41 | -326,438,252.43 | 11,979,756.66 | 38,102,495.42 |
| 归属于少数股东的综合收益总额 | -916,507.29 | -3,620,266.54 | -1,745,444.04 | -1,383,776.54 |
| 公告日期 | 2025-04-29 | 2025-04-29 | 2024-10-31 | 2024-08-31 |
| 审计意见(境内) | | 标准无保留意见 | | |